Status:
COMPLETED
A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizophrenia
Bipolar Disorder
Eligibility:
All Genders
10-17 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of oral ziprasidone in children and teens with psychotic disorders
Eligibility Criteria
Inclusion
- Children and teens with Bipolar I Disorder (manic or mixed), schizophrenia or schizoaffective disorder
- Willingness to discontinue all antipsychotic medications during the study period
Exclusion
- Patients who are clinically stable on treatments that are well tolerated
- Substance-induced psychotic disorders
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00650611
Start Date
December 1 2003
End Date
March 1 2005
Last Update
February 21 2021
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
San Diego, California, United States, 92111
2
Pfizer Investigational Site
Altamonte Springs, Florida, United States, 32701
3
Pfizer Investigational Site
Libertyville, Illinois, United States, 60048
4
Pfizer Investigational Site
Lexington, Kentucky, United States, 40509